Pasithea Therapeutics
KTTA
11 hedge funds and large institutions have $217K invested in Pasithea Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
119% more capital invested
Capital invested by funds: $99.1K → $217K (+$118K)
38% more funds holding
Funds holding: 8 → 11 (+3)
1.12% more ownership
Funds ownership: 2.91% → 4.04% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$153K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$51.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$41.3K |
| 4 |
LPL Financial
San Diego,
California
|
+$10.9K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$1.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$17.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $140K | +$153K | +140,000 | +261% |
|
|
2
Citadel Advisors
Miami,
Florida
| $33.8K | +$51.2K | +46,858 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $30.4K | +$41.3K | +37,805 | +872% |
|
|
4
LPL Financial
San Diego,
California
| $7.21K | +$10.9K | +10,000 | New |
|
|
HC
5
Hurley Capital
New York
| $2.66K | – | – | – |
|
|
6
Raymond James Financial
St Petersburg,
Florida
| $1.14K | +$1.73K | +1,584 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $910 | -$2.19K | -2,006 | -61% |
|
|
SS
8
SBI Securities
Tokyo,
Japan
| $758 | +$1.15K | +1,051 | New |
|
9
JP Morgan Chase
New York
| $108 | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $44 | +$59 | +54 | +675% |
|
|
11
Citigroup
New York
| – | -$17.8K | -13,706 | Closed |
|
KTTA Hedge Fund Activity: Q2 2025 in Review
11 of the 7,602 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q2 2025, worth a combined $217K — up 119% from $99.1K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KTTA positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $153K. The largest seller was Citigroup, exiting entirely with an estimated $17.8K sold.
- 11 institutional investors held Pasithea Therapeutics (KTTA) as of Q2 2025, up from 8 in Q1 2025.
- Funds reported $217K of Pasithea Therapeutics stock for Q2 2025, up 119% quarter-over-quarter.
- 4 funds opened new Pasithea Therapeutics positions in Q2 2025 and 1 closed out, a net change of +3 holders.
- The largest Pasithea Therapeutics buyer in Q2 2025 was AdvisorShares Investments, an estimated $153K added.
- The largest Pasithea Therapeutics seller in Q2 2025 was Citigroup, an estimated $17.8K sold.
Based on aggregated 13F filings for Q2 2025.